The present study shows that the EE condition implemented from infancy to adulthood prevents behavioral and hippocampal molecular alteration induced by the two-hit model of schizophrenia. Besides this, the main novelty of our study is that the two-hit model simulates Slc6a4 gene methylation alterations observed in schizophrenia patients 35. At the same time, EE condition mitigated hippocampal pro-inflammatory and alterations in Slc6a4 gene methylation.
Our study applied a 7-week EE protocol in mice submitted to a neurodevelopmental model induced by a first hit in neonatal life, whose molecular alterations are progressive along life 9. Notably, the duration of EE has an important impact on behavioral and molecular outcomes. In this regard, a 3-week EE implementation in adult mice improved aversive stimulus-based memory performances and reduced anxiety-like behavior, while a 5-week exposure caused no obvious alteration 36. On the other hand, mice submitted to a maternal separation protocol from PNDs 1–21 and to EE condition from PNDs 23 to 65 (6 weeks duration) were protected against the effects of maternal separation, i.e., had lower anxiety levels and reversed spatial memory deficits compared with animals housed in standard conditions. Additionally, in this 6 weeks EE protocol, the protective effect of EE was associated with hippocampal increased expression of BDNF and synaptophysin 37. Hence, EE protocols with longer durations seem more efficient in preventing or correcting long-term alterations induced by early-life adversities.
The effect of EE condition during puberty on the development of long-term behavioral alterations has also been investigated in other animal models of schizophrenia 38,39. A recent study using an animal model based on repeated N-methyl-D-aspartate receptor (NMDAR) antagonist MK801 administration during adolescence observed structural excitatory/inhibitory imbalance significantly correlated with animal recognition memory deficits, which EE prevented. Additionally, these authors showed that the selective chemogenetic activation of axonal bouton of parvalbumin-expressing interneurons (PVIN) in the frontal association cortex mimicked the effects of EE on both synaptic plasticity and animal behavior. In contrast, selective inhibition of PVIN abolished EE's beneficial effects. The same behavioral and molecular alterations induced by EE and PVIN manipulation were observed in adolescent PV-Cre; ErbB4fl/fl mice 40. It should be mentioned that PVINs are fast-spiking GABAergic interneurons that provide inhibitory control of cortical and subcortical circuits, thought to be a key alteration underlying schizophrenia 41. Furthermore, PVINs in the hippocampus are crucial in schizophrenia cognitive dysfunction 42. Importantly, PVINs are susceptible to oxidative and inflammatory CNS microenvironmental alterations, as observed in several animal models of schizophrenia 43, including the ones based on perinatal immune activation.
In our results, we observed that EE could prevent hippocampal inflammatory changes, i.e., abolish the increase in IBA-1 protein expression induced by the two-hit model of schizophrenia while also increasing neurogenesis (observed by DCX protein expression). In the two-hit model, the first hit is exposure to PolyI:C, which induces innate immune cell activation via Toll-like receptors (TLRs). PolyI:C selectively stimulates TLR3 proinflammatory cytokine production 44. PolyI:C exposure early in life induces microglial priming, a state in which the cells respond more to stimuli. In summary, early life exposure to PolyI:C may lead to changes in microglial state and function, priming these cells for subsequent immune challenges, not beneficial to brain function 45, i.e., leading to behavioral alterations such as cognitive deficits.
Additionally, peripubertal stress may increase proinflammatory cytokines and contribute to a lasting pro-inflammatory state46. These immune alterations influence critical neurotransmission systems relevant to schizophrenia, such as dopaminergic, serotonergic, and glutamatergic. Additionally, the enzyme indoleamine 2,3-dioxygenase (IDO) of the tryptophan/5-HT/kynurenine metabolism has its expression and activity increased by immune activation, influencing the serotonergic and glutamatergic neurotransmission via the metabolites quinolinic (an NMDAR agonist) and kynurenic acid (an NMDAR antagonist), a mechanism underlying schizophrenia 47.
Many preclinical studies have evaluated EE's effects on neuroinflammation markers, but as far as we know, no one has used the two-hit model of schizophrenia. In the short term, EE was a stronger microglial and peripheral T cell modulator in C57BL/6 wild-type mice 48. On the other hand, another study showed that long-term EE reduced the inflammatory cytokines and increased hypertrophy and ramification of IBA1 in the hippocampus, hypothalamus, and amygdala without altering microglial cell density 49. Once more, considering these studies that relate time and the beneficial effect of EE, the literature report that EE's degree of preventive and therapeutic effects on schizophrenia abnormalities may vary depending on age and duration of exposure 50,51.
Great attention has been directed to the role of 5-HT in short- and long-term memory, cognition, mood, impulse control, and motor performance in psychiatric disorders such as schizophrenia 52. Indeed, 5-HT modulates dopaminergic neurotransmission, the core neurotransmission system of schizophrenia pathophysiology and treatment 53, being the combined blockage of D2 and 5HT2A receptors, the main mechanism of atypical antipsychotic drugs 54. Deserves mentioning that the hippocampus has a great expression of the 5-HTT in the stratum oriens of area CA3 and, to a lesser extent, in the stratum oriens of CA1 and the stratum lacunosum moleculare of CA1-CA3 55.
Our results showed that the Slc6a4 gene was partially methylated (50%) in all hippocampal samples of the two-hit group. As far as we know, this is the first evidence of such alteration in a two-hit animal model of schizophrenia. Indeed, since the 5-HTT plays a critical role in regulating serotonergic function, it was observed that polymorphisms in this gene are related to psychosis, depressive-related symptoms, and suicidal behavior in patients with schizophrenia 56,57. Furthermore, altered SLC6A4 gene methylation is observed in stress-related psychiatric disorders 58. Regarding schizophrenia, lower SLC6A4 mRNA expression was observed in drug-naive first-episode patients, whereas antipsychotic treatment had no significant effect on the expressions of SLC6A4 mRNA over an 8-week follow-up 59. We observed that EE could demethylate the Slc6a4 gene in our animal model. Hence, based on our results, we can infer that EE effects in Slc6a4 gene methylation may be of great relevance in preventing or as an adjunct to the mechanisms of antipsychotic drugs. Furthermore, our results are promising for developing epigenetic drugs (the so-called epidrugs) for being used as preventive strategies or pharmacological treatment of schizophrenia patients, alone or combined with environmental interventions.
This study has some limitations. Firstly, we used only male mice. Since schizophrenia presents a sex bias, using male and female mice would be important. Despite this, the disorder in males, as previously mentioned, has more severe symptoms and early onset. Additionally, males are more prone to developing neurodevelopmental disorders than females, probably due to sex differences in immune response 24. Secondly, we did not evaluate 5-HTT protein expression.
In conclusion, the present study provides novel evidence on altered hippocampal Slc6a4 gene methylation in an animal model of schizophrenia induced by two-hit. Furthermore, a 7-week EE implementation could abrogate behavioral impairment, Slc6a4 gene methylation, and proinflammatory hippocampal alterations induced by the model, an important alternative for schizophrenia prevention. This study brings new insights into molecular-targeted schizophrenia therapies based on environmental manipulation and epigenetic-driven approaches to target schizophrenia prevention and treatment strategies.